Roquette To Inject 60 Million Yuan Into Guangxi Nanning Chemical Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
Guangxi Nanning Chemical Pharmaceutical, one of China's largest medical mannitol producers, has confirmed that French Roquette is increasing its share acquisition. According to the exclusive restructuring agreement, Roquette will raise its Nanning Chemical stake to 67 percent. It will pump in an initial investment of 60 million yuan in 2008 to revamp the existing production line and set up new hexahydric alcohol and crystal sorbitol lines to double the current annual output of 8,000 and 3,000 tons respectively. A Nanning Chemical source revealed that the company plans to establish a medical mannitol production base after the reorganization, but no details are yet available. (Click here for more - Chinese Language)
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.